DNA vaccine with immunotherapy can treat HPV

A new vaccine therapy has the ability to produce an immune response in patients with head and neck squamous cell carcinoma, also known as HNSCCa, in patients with papilloma virus or HPV.

Accordingly, researchers at the Abramson Cancer Center at the University of Pennsylvania have created a new vaccine capable of producing an immune response in patients with HNSCC by targeting HPV, a sexually transmitted disease. sex, related to HNSCCa.

HPV is one of the most common sexually transmitted diseases, according to the US Centers for Disease Control and Prevention (CDC), and nearly all sexually active adults will get it. some time.

HNSCCa is a type of cancer that develops in the mucous membrane of the mouth and throat. Common causes of HNSC include smoking, and HPV infection.

Nearly 70 percent of throat cancers in the United States are related to HPV, of which 60 percent is caused by a type of HPV disease called HPV 16/18.

Dr Charu Aggarwal, an expert on cervical cancer, said: "This is a new type of disease that we target with this new therapy, and we are the only group in the US to prove it. Effective immune activation with this immunosuppressive vaccine is based on DNA for cervical cancer HPV 16/18 " - He said in a press release.

In this study, the researchers treated 22 patients with the vaccine, injected as an injection of modulated antigens straight from the DNA into the immune system to begin producing antibodies and activating them. Immune cells kill germs. At the same time, doctors have used a special device to provide an electrical pulse to the area to stimulate muscles around the area to accelerate antigen consumption.

" The data shows that this DNA vaccine has been targeted properly, specifically, safely and well tolerated, " Aggarwal said.

This study was presented at the 2017 American Clinical Cancer Annual Meeting in Chicago.